This means there is no established pharmacological mechanism by which semaglutide would be expected to cause spotting or bleeding between periods
diabetes, obesity, high body mass index (BMI) score), while 48% are taking them for personal weight loss reasons
Clinical and Experimental Immunology, 185 (1), 121
- October 24, 2025 - Rose Pharma Inc., a clinical-stage biopharmaceutical company developing ROSE-010, a rapid-onset, short-duration GLP-1 therapy targeting both weight management and acute IBS pain, today announced that Chief Executive Officer Enda Kenny, PhD will present data from its recent clinical trial in weight management at #ObesityWeek2025 (sponsored by The Obesity Society) on Tuesday, November 4, 2025 at 7:30 p.m